hetrombopag olamine + standard therapy

Hetrombopag olamine is the orally active ethanolamine salt of hetrombopag, a small-molecule nonpeptide thrombopoietin receptor (TPO-R or CD110) agonist. It stimulates the transmembrane domain of the platelet TPO-R to promote proliferation and differentiation of megakaryocytic lineage cells and increase platelet production. This mechanism is used to treat thrombocytopenia in conditions such as immune thrombocytopenia (ITP) and severe aplastic anaemia (SAA), especially in patients who have not responded to or relapsed after first-line therapies like corticosteroids. "Standard therapy" typically refers to established treatments for ITP or SAA—most commonly corticosteroids for ITP—but may also include immunosuppressants or other supportive care depending on disease context[1][3][4][6]. The combination "hetrombopag olamine + standard therapy" thus refers to using hetrombopag alongside these established regimens.

Brand names

Hengqu

Other names

SHR-8735 olamineSHR8735 olamineSHR 8735 olamineHetrombopag diolamineHetrombopag ethanolamineHerombopag olamineHytrapopapa ethanolamineHytrapopapamin